L. gasseri

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion weight immunity

Research Overview

Overall, research on Lactobacillus gasseri has most heavily focused on its role as a human mucosa–adapted commensal, particularly in the vaginal ecosystem, and secondarily on gastrointestinal/metabolic outcomes. Vaginal microbiome surveys in healthy women identify community states dominated by specific Lactobacillus species (including L. gasseri) and link these states to ecological functions such as lactic acid production and lower vaginal pH, with inter-individual and ethnicity-associated variation in community composition and pH. In parallel, multiple in vitro studies have characterized vaginal L. gasseri isolates for mechanistic traits relevant to urogenital health—adhesion to epithelial cell models, co-aggregation with pathogens, biofilm formation (often in multi-strain consortia), and antimicrobial activity mediated by organic acids, hydrogen peroxide, and in some strains bacteriocins—along with anti-adhesion effects against Candida spp. Additional work in non-vaginal contexts includes screening of infant-feces isolates for acid/bile tolerance and immunomodulatory activity in macrophage models, and animal studies of specific strains (e.g., BNR17) for effects on adiposity and glucose-related endpoints.

The strongest evidence supported by these abstracts is that L. gasseri is a common component of healthy, Lactobacillus-dominated vaginal communities and possesses plausible protective mechanisms in vitro that could contribute to vaginal homeostasis and pathogen exclusion. These mechanisms include robust lactic acid production (D- and L-isomers), strain-dependent production of hydrogen peroxide and bacteriocins, and measurable inhibition of growth and/or adhesion of diverse urogenital pathogens in cell-free supernatants and epithelial cell assays; together, these findings provide convergent mechanistic support for a protective role, while also emphasizing strong strain specificity. For systemic outcomes (e.g., obesity/diabetes-related phenotypes), the evidence in these abstracts is suggestive but primarily preclinical: in mice, administration of L. gasseri BNR17 reduced weight gain and adipose mass and shifted expression of lipid oxidation/synthesis genes and glucose transport markers, indicating biological plausibility but not establishing clinical efficacy.

Key gaps include the need for well-powered, strain-resolved human clinical trials that connect specific L. gasseri strains (alone and in defined consortia) to clinically meaningful endpoints such as bacterial vaginosis recurrence, vulvovaginal candidiasis prevention/adjunctive therapy, and sexually transmitted infection risk, with standardized outcomes (e.g., Nugent score, pH, symptom scores) and longitudinal microbiome tracking to confirm durable colonization. Mechanistically, more work is needed to disentangle which metabolites and proteins (organic acids, bacteriocins, potential epigenetic targets such as histone deacetylases) drive antifungal and antibacterial effects in vivo, and how host factors and baseline community state modify responses. For metabolic and immune indications, translation requires rigorous human studies with clear strain identification, dosing, and mechanistic biomarkers, since current support is largely from animal models and in vitro immunology assays.

1. What conditions has L. gasseri been studied for?

  • Vaginal microbiome states and vaginal health (including bacterial vaginosis risk markers): L. gasseri is one of the dominant “community state types” identified in asymptomatic women, and community patterns were associated with high vs low Nugent scores (a BV diagnostic metric) and vaginal pH differences across ethnic groups.

  • Urogenital infections/pathogen inhibition (in vitro): Vaginal L. gasseri strains were tested against multidrug-resistant urogenital bacteria (e.g., E. coli, K. pneumoniae, S. agalactiae, S. aureus, P. aeruginosa) and against Candida species (C. albicans, C. glabrata, etc.) in mechanistic and antimicrobial assays.

  • Vulvovaginal candidiasis-related mechanisms (in vitro): Specific vaginal L. gasseri isolates (e.g., BC10, BC11) were studied for reducing Candida adhesion to epithelial cells and for supernatant-mediated antifungal effects.

  • Biofilm modulation (in vitro): Exopolysaccharides (EPS) from vaginal L. gasseri strains were studied for stimulating Lactobacillus biofilms and inhibiting pathogen biofilms (bacterial and fungal).

  • Metabolic outcomes (animal models): L. gasseri BNR17 was studied in mice/rats for diet-associated weight gain/adiposity and glucose/insulin-related outcomes (high-sucrose diet models).

  • Inflammation/immune signaling and metabolic enzyme targets (cell/in vitro): Infant-feces-derived L. gasseri (e.g., strain 4M13) was tested for effects on oxidative stress measures, α-glucosidase inhibition, cholesterol-lowering assays, and LPS-stimulated macrophage cytokines (TNF-α, IL-6, IL-1β, IL-10).

  • Assisted reproductive technology (ART) outcomes (observational human study): A vaginal microbiome type “predominant in L. gasseri” was associated with lower ART success compared with L. crispatus-predominant or mixed lactic-acid-bacteria-predominant types.

  • Other clinical areas mentioned (review-level statement): A review abstract states clinical trial data support roles in maintaining vaginal homeostasis, mitigating Helicobacter pylori infection, and ameliorating diarrhea (details not provided in the supplied text).

2. Does it work in treating those conditions? Summarize the evidence.

  • Urogenital bacterial pathogens (in vitro): Vaginal strains including L. gasseri 1A-TV showed “strong bactericidal” effects of cell-free supernatants against multiple multidrug-resistant urogenital pathogens, with exceptions (notably Enterococcus faecium and E. faecalis were less affected). Activity was heat-stable but decreased with enzymatic treatment, suggesting proteinaceous factors (e.g., bacteriocins) contribute.

  • Candida (in vitro): In one study, most Lactobacillus strains reduced C. albicans adhesion to HeLa cells; specifically, L. gasseri BC10 and BC11 were among the most active in reducing adhesion via both cells and supernatants. However, in another antimicrobial/co-aggregation study, lactobacilli co-aggregated with many urogenital pathogens “except for Candida spp.” (suggesting strain- and endpoint-dependence).

  • Biofilms (in vitro): EPS from vaginal L. gasseri strains inhibited biofilm formation of bacterial and fungal pathogens in a dose-dependent manner, with reported inhibition “up to 86%” at 1 mg/mL and stronger effects overall than EPS from L. crispatus in that dataset. The same EPS also increased Lactobacillus biofilm biomass/viability (potentially supporting colonization).

  • Weight/adiposity and glycemic markers (animal evidence): In high-sucrose-fed mice, L. gasseri BNR17 reduced body weight and white adipose tissue weight at both 109 and 1010 CFU doses over 10 weeks, increased expression of fatty-acid oxidation genes (ACO, CPT1, PPARα, PPARδ), decreased lipogenesis genes (SREBP-1c, ACC), increased GLUT4 expression, and reduced serum leptin and insulin. This supports efficacy in that animal model, but it is not direct proof of clinical weight-loss or diabetes treatment in humans.

  • Inflammation/cytokines and metabolic targets (cell/in vitro): L. gasseri 4M13 reduced nitric oxide production and inhibited release of inflammatory mediators (TNF-α, IL-6, IL-1β, IL-10) in LPS-stimulated RAW 264.7 macrophages, and showed relatively higher antioxidant, α-glucosidase inhibition, and cholesterol-lowering activity versus other screened strains. These are mechanistic/functional assays, not clinical treatment evidence.

  • ART outcomes (observational association): Women with an L. gasseri-predominant vaginal microbiome had lower ART success than women with L. crispatus-predominant or mixed lactic-acid-bacteria-predominant types. This does not test L. gasseri as a treatment; it suggests that an L. gasseri-dominant state may be a less favorable biomarker for implantation success in that cohort.

  • Overall: The strongest “works” signals in the provided abstracts are in vitro antimicrobial/anti-biofilm activity and animal-model metabolic effects. Multiple abstracts explicitly note the need for in vivo/human clinical studies to confirm benefits for infection prevention/treatment.

3. What health benefits does it have?

  • Supports vaginal ecosystem functions (contextual evidence): L. gasseri is one of the Lactobacillus species that can dominate healthy vaginal communities, consistent with the broader concept that Lactobacillus-dominant states help maintain low pH and pathogen resistance.

  • Antimicrobial activity against urogenital bacteria (strain-dependent): Vaginal L. gasseri strains produced metabolites (including D- and L-lactic acid; some strains also produced hydrogen peroxide and bacteriocins such as helveticin J/acidocin A in the mixed-strain study) and their supernatants showed bactericidal activity against many multidrug-resistant urogenital pathogens (with notable Enterococcus exceptions).

  • Anti-adhesion effects against Candida (strain-dependent): Certain vaginal L. gasseri strains (BC10, BC11) reduced C. albicans adhesion to epithelial cells via both whole cells and secreted factors, suggesting a potential role in prophylaxis/adjuvant strategies for Candida infections.

  • Biofilm-related benefits: L. gasseri-derived EPS stimulated Lactobacillus biofilm formation (increasing biomass and viability) while inhibiting pathogen biofilms (including Candida spp.), which could theoretically support colonization resistance.

  • Metabolic benefits in animal models: L. gasseri BNR17 reduced weight gain and adiposity and improved gene-expression markers consistent with increased fat oxidation and improved glucose handling (e.g., increased GLUT4; reduced insulin and leptin) in high-sucrose-fed mice.

  • Immunomodulatory/anti-inflammatory signals (preclinical): L. gasseri 4M13 reduced LPS-stimulated inflammatory mediator release in macrophages and showed favorable functional assay results (antioxidant, α-glucosidase inhibition, cholesterol-lowering), suggesting possible cardiometabolic/immune relevance—pending human confirmation.

4. Does it have any downsides or side effects?

  • Potential downside in fertility/ART context (association, not causation): In the ART cohort study, an L. gasseri-predominant vaginal microbiome type was associated with lower ART success compared with L. crispatus-predominant or mixed lactic-acid-bacteria-predominant types. This does not prove harm from supplementation, but it raises a caution that “Lactobacillus-dominant” is not always equivalent across species for reproductive outcomes.

  • Not universally active against all pathogens: In vitro, L. gasseri-containing preparations showed weaker activity against some organisms (e.g., Enterococcus faecium and E. faecalis in one study), and co-aggregation effects were reported as limited “except for Candida spp.” in another. This is a limitation rather than a safety issue, but it matters for expectations.

  • Side effects not reported in these abstracts: The provided abstracts do not describe adverse events in humans. The metabolic study is in mice and reports beneficial metabolic changes but does not detail tolerability outcomes. Therefore, human side-effect frequency and severity cannot be concluded from these abstracts.

  • General limitation: Many findings are strain-specific (e.g., BNR17 vs BC10/BC11 vs 1A-TV vs 4M13) and based on in vitro/animal work; extrapolating to consumer products without matching strain and dose is a key practical downside.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The supplied abstracts do not report pharmacogenomic interactions (i.e., effects modified by human genetic variants) for L. gasseri.

  • No direct evidence provided: None of the abstracts link L. gasseri response or safety to specific host genotypes (e.g., immune, metabolic, or mucosal barrier gene variants).

  • Indirect/related points (not pharmacogenomics): One study reports statistically significant differences in vaginal community types across ethnic groups and differences in vaginal pH by ethnicity; however, ethnicity is not a genetic-variant analysis and cannot be used to infer pharmacogenomic effects.

  • Strain genomics ≠ host pharmacogenomics: One abstract reports whole-genome sequencing identifying L. gasseri 4M13 as a novel genomic strain, which informs microbial genetics but does not establish host genotype-specific benefit or harm.

References

  1. Vaginal microbiome of reproductive-age women.
    Jacques Ravel, Pawel Gajer, Zaid Abdo, G Maria Schneider, Sara S K Koenig, Stacey L McCulle, Shara Karlebach, Reshma Gorle, Jennifer Russell, Carol O Tacket, Rebecca M Brotman, Catherine C Davis, Kevin Ault, Ligia Peralta, Larry J Forney (2011) - Proceedings of the National Academy of Sciences of the United States of America
  2. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens.
    Marina Scillato, Ambra Spitale, Gino Mongelli, Grete Francesca Privitera, Katia Mangano, Antonio Cianci, Stefania Stefani, Maria Santagati (2021) - MicrobiologyOpen
  3. Probiotic and anti-inflammatory potential of Lactobacillus rhamnosus 4B15 and Lactobacillus gasseri 4M13 isolated from infant feces.
    Nam Su Oh, Jae Yeon Joung, Ji Young Lee, Younghoon Kim (2018) - PloS one
  4. Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity.
    Carola Parolin, Antonella Marangoni, Luca Laghi, Claudio Foschi, Rogers Alberto Ñahui Palomino, Natalia Calonghi, Roberto Cevenini, Beatrice Vitali (2015) - PloS one
  5. Lactobacillus iners and genital health: molecular clues to an enigmatic vaginal species.
    Johanna B Holm, Kayla A Carter, Jacques Ravel, Rebecca M Brotman (2023) - Current infectious disease reports
  6. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice.
    Ji-Hee Kang, Sung-Il Yun, Mi-Hee Park, Jun-Hong Park, So-Young Jeong, Han-Oh Park (2013) - PloS one
  7. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
    Kurt Selle, Todd R Klaenhammer (2013) - FEMS microbiology reviews
  8. Lactobacillus crispatus-dominated vaginal microbiome and Acinetobacter-dominated seminal microbiome support beneficial ART outcome.
    Kairi Koort, Kristiina Sõsa, Silver Türk, Eleri Lapp, Elle Talving, Peeter Karits, Karin Rosenstein, Madis Jaagura, Aire Sekavin, Deniss Sõritsa, Kai Haldre, Helle Karro, Paul Korrovits, Andres Salumets, Reet Mändar (2023) - Acta obstetricia et gynecologica Scandinavica
  9. Proteomic characterization of extracellular vesicles derived from lactic acid bacteria.
    Bao-Hong Lee, You-Zuo Chen, Tang-Long Shen, Tzu-Ming Pan, Wei-Hsuan Hsu (2023) - Food chemistry
  10. Exopolysaccharides from vaginal lactobacilli modulate microbial biofilms.
    Barbara Giordani, Marina Naldi, Vanessa Croatti, Carola Parolin, Ülfet Erdoğan, Manuela Bartolini, Beatrice Vitali (2023) - Microbial cell factories
  11. Lactobacilli extracellular vesicles: potential postbiotics to support the vaginal microbiota homeostasis.
    Vanessa Croatti, Carola Parolin, Barbara Giordani, Claudio Foschi, Stefano Fedi, Beatrice Vitali (2022) - Microbial cell factories
  12. Orally administrated
    Fengyuan Qi, Shangrong Fan, Chao Fang, Lan Ge, Jinli Lyu, Zhuoqi Huang, Shaowei Zhao, Yuanqiang Zou, Liting Huang, Xinyang Liu, Yiheng Liang, Yongke Zhang, Yiyi Zhong, Haifeng Zhang, Liang Xiao, Xiaowei Zhang (2023) - Frontiers in immunology
  13. Inhibitory Effect of Vaginal Lactobacillus Supernatants on Cervical Cancer Cells.
    Ke-Di Wang, Dong-Jiang Xu, Bao-Ya Wang, Dong-Hui Yan, Zhi Lv, Jian-Rong Su (2018) - Probiotics and antimicrobial proteins
  14. Intestinal microbiota imbalance resulted by anti-Toxoplasma gondii immune responses aggravate gut and brain injury.
    Jiating Chen, Chi Zhang, Zihan Yang, Weiling Wu, Weihao Zou, Zixuan Xin, Shuyu Zheng, Runchun Liu, Lili Yang, Hongjuan Peng (2024) - Parasites & vectors
  15. Lactobacillus gasseri ATCC33323 affects the intestinal mucosal barrier to ameliorate DSS-induced colitis through the NR1I3-mediated regulation of E-cadherin.
    Guanru Qian, Hui Zang, Jingtong Tang, Hao Zhang, Jiankang Yu, Huibiao Jia, Xinzhuang Zhang, Jianping Zhou (2024) - PLoS pathogens
  16. Diverse Expression of Antimicrobial Activities Against Bacterial Vaginosis and Urinary Tract Infection Pathogens by Cervicovaginal Microbiota Strains of
    Fabrice Atassi, Diane L Pho Viet Ahn, Vanessa Lievin-Le Moal (2019) - Frontiers in microbiology
  17. Lactobacillus Biofilms Influence Anti-Candida Activity.
    Carola Parolin, Vanessa Croatti, Luca Laghi, Barbara Giordani, Maria Rosaria Tondi, Priscilla Romina De Gregorio, Claudio Foschi, Beatrice Vitali (2021) - Frontiers in microbiology
  18. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia.
    Luisa Marras, Michele Caputo, Sonia Bisicchia, Matteo Soato, Giacomo Bertolino, Susanna Vaccaro, Rosanna Inturri (2021) - Microorganisms
  19. Lactobacillus iners and gasseri, Prevotella bivia and HPV Belong to the Microbiological Signature Negatively Affecting Human Reproduction.
    Giuseppina Campisciano, Valerio Iebba, Gabriella Zito, Stefania Luppi, Monica Martinelli, Leo Fischer, Francesco De Seta, Giuseppe Basile, Giuseppe Ricci, Manola Comar (2020) - Microorganisms
  20. The association between vaginal microbiota and female infertility: a systematic review and meta-analysis.
    Xiang Hong, Jun Ma, Jiechen Yin, Shenghao Fang, Jia Geng, Hongxia Zhao, Mengwen Zhu, Meng Ye, Xiaoyue Zhu, Yan Xuan, Bei Wang (2020) - Archives of gynecology and obstetrics


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!